[NH2:1][C:2]1[CH:3]=[C:4]([CH:8]([NH:13][C:14]2[C:23]3[C:18](=[C:19]([C:24]([NH2:26])=[O:25])[CH:20]=[CH:21][CH:22]=3)[N:17]=[CH:16][N:15]=2)[CH2:9][CH2:10][O:11][CH3:12])[CH:5]=[CH:6][CH:7]=1.Cl.CN(C)CCCN=C=NCC.N1(O)C2C=CC=CC=2N=N1.[F:49][C:50]([F:62])([F:61])[O:51][C:52]1[CH:60]=[CH:59][C:55]([C:56](O)=[O:57])=[CH:54][CH:53]=1.C(N(C(C)C)C(C)C)C>CN(C=O)C>[CH3:12][O:11][CH2:10][CH2:9][CH:8]([NH:13][C:14]1[C:23]2[C:18](=[C:19]([C:24]([NH2:26])=[O:25])[CH:20]=[CH:21][CH:22]=2)[N:17]=[CH:16][N:15]=1)[C:4]1[CH:5]=[CH:6][CH:7]=[C:2]([NH:1][C:56](=[O:57])[C:55]2[CH:59]=[CH:60][C:52]([O:51][C:50]([F:49])([F:61])[F:62])=[CH:53][CH:54]=2)[CH:3]=1A mixture of 4-{[1-(3-aminophenyl)-3-methoxypropyl]amino}quinazoline-8-carboxamide (50.00 mg; 0.14 mmol; 1.00 eq.), N-[3-(dimethylamino)propyl]-N′-ethylcarbodiimide hydrochloride (30 mg; 0.16 mmol; 1.10 eq.) and 1H-1,2,3-benzotriazol-1-ol (22 mg; 0.16 mmol; 1.10 eq.) in dry DMF (1 mL) were added 4-(trifluoromethoxy)benzoic acid (33 mg; 0.16 mmol; 1.10 eq.) and N-ethyl-N-isopropylpropan-2-amine (0.08 ml; 0.43 mmol; 3.00 eq.). The mixture was stirred overnight. After concentration, the crude was purified by reverse phase HPLC to obtain 26 mg of the title product in 34% yield. LCMS [540 (M+1)]. 1H NMR (400 MHz, DMSO-D6): 2.1875 (m, 1H), 2.3432 (m, 1H), 3.2379 (s, 3H), 3.3835 (m, 1H), 3.4522 (m, 1H), 5.7150 (m, 1H), 7.0524 (m, 2H), 7.2017 (m, 1H), 7.3317 (m, 1H), 7.6285 (m, 1H), 7.9371 (m, 6H), 8.0791 (m, 1H), 8.5544 (m, 1H), 8.6647 (s, 1H), 8.8136 (s, 1H), 10.3786 (s, 1H).